What is Kuano?
Founded in 2020, Kuano operates at the intersection of computational chemistry and artificial intelligence. The company has developed a sophisticated software platform that enables rapid, cost-effective quantum modeling of enzymes, a process traditionally hindered by high computational costs and time-intensive laboratory cycles. By digitizing the drug discovery process, Kuano is effectively shortening the timeline for identifying viable therapeutic candidates. The company is currently leveraging this technology to advance its internal pipeline of novel therapeutics targeting significant unmet medical needs, while simultaneously engaging in strategic collaborative programs with both academic institutions and commercial pharmaceutical partners to validate its platform across diverse therapeutic areas.
How much funding has Kuano raised?
Kuano has raised a total of $3.6M across 2 funding rounds:
Angel/Seed
$1.4M
Angel/Seed
$2.2M
Angel/Seed (2021): $1.4M with participation from o2h Ventures and ACF Investors
Angel/Seed (2023): $2.2M led by Mercia Technologies, Ascension Ventures, and o2h ventures
Key Investors in Kuano
Mercia Technologies
Mercia Asset Management provides equity and debt financing to UK businesses with growth ambitions, acting as investment partners from scale-up to exit.
Ascension Ventures
Ascension is a venture capital firm that specializes in backing early-stage tech businesses addressing societal challenges, with a focus on impact-driven investments.
o2h ventures
o2h Ventures is a UK-based specialist biotech fund that focuses on transforming biotech breakthroughs into impactful solutions through SEIS/EIS and growth-stage funding.
What's next for Kuano?
With this major strategic investment, Kuano is well-positioned to accelerate its R&D roadmap and solidify its market position as a leader in quantum-driven biotech innovation. The company is expected to prioritize the expansion of its internal therapeutic pipeline, moving closer to clinical-stage development for its lead assets. Furthermore, the influx of capital will likely facilitate the scaling of its computational infrastructure and the recruitment of top-tier talent in quantum chemistry and machine learning. By deepening its collaborative partnerships, Kuano aims to demonstrate the scalability of its platform, potentially setting a new standard for efficiency in the global drug discovery landscape.
See full Kuano company page
